The FDA approved Sage Therapeutics Inc (NASDAQ: SAGE) and Biogen Inc's (NASDAQ: BIIB) Zurzuvae (zuranolone) 50 mg for adults with postpartum depression (PPD) but issued a Complete Response Letter
Operator: Good morning and welcome to Cerevel Therapeutics Second Quarter Financial Results Conference Call. At this time, all participants are in listen-only mode.
Operator: Good day and thank you for standing by. Welcome to the Coherus Biosciences Second Quarter 2023 Conference Call. At this time all participants are in a listen-only mode.
Operator: Good day, and thank you for standing by. Welcome to Apellis Pharmaceuticals Second Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode.
(Bloomberg) Apellis Pharmaceuticals Inc. shares suffered their worst two-day drop on record after confirming reports that some patients experienced severe inflammation following treatment with its eye drug.Most Read from BloombergTesla Investor Rode a 14,800% Gain Thanks to 27-Year-Old AnalystSingapore Passport Is World’s Most Powerful, Replacing JapanMassive US Oil Caverns Sit Empty and Will Take Years to RefillMeet the Billionaire Who Convinced Messi to Pick MLS Over Saudi ArabiaTrump Gets